がん特異的なユビキチンリガゼによるAMPKの劣化
Carlos T Pineda1, Saumya Ramanathan1, Klementina Fon Tacer1
1Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|February 14, 2015
まとめ
癌細胞は,MAGE-A3/6-TRIM28.28を含む生殖系メカニズムをハイジャックすることによって,AMP活性化タンパク質キナーゼ (AMPK) を抑制する. これはAMPKα1の分解につながり,がんの成長を促進し,AMPKを標的とする薬に対する感受性を高めます.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 細胞の代謝について
背景:
- AMP活性化タンパク質キナーゼ (AMPK) は,細胞エネルギーホメオスタシスの重要な調節体であり,代謝ストレス中にアナボリックプロセスを抑制し,転化を促進します.
- 癌細胞は,上流の調節キナーゼの変異を含む様々なメカニズムを通じて,AMPKの成長制限機能を回避することができます.
- MAGE-A3とMAGE-A6は,通常,男性生殖系に限定されるタンパク質ですが,ヒトがんでは頻繁に再活性化され,腫瘍細胞の生存に不可欠です.
研究 の 目的:
- 癌細胞がAMPKの活動を抑制する新しいメカニズムを解明する.
- 癌におけるMAGE-A3/6-TRIM28ユビキチンリガゼ複合体の特定の標的と機能を特定する.
- 癌の進行と治療戦略に対するAMPK抑制の影響を理解する.
主な方法:
- MAGE-A3/6-TRIM28ユビキチンリガゼ複合体の標的を特定するためにスクリーニングアッセイを使用しました.
- MAGE-A3/6-TRIM28.2によるAMPKα1の直接標的化を確認するために,ユビキチネーションアッセイを行った.
- AMPKα1の分解がオートファジー,mTORシグナル伝達,およびメトホルミンなどのAMPKアゴニストに対する細胞応答に及ぼす機能的影響を評価した.
主要な成果:
- 特定されたMAGE-A3/6-TRIM28は,特にAMPKα1.1.をターゲットにして分解するユビキチンリガゼである.
- MAGE-A3 / 6媒介のAMPKα1の分解がオートファギーの抑制につながることを実証しました.
- AMPKの抑制は,mTOR経路の活性化と,AMPKアゴニストに対する癌細胞の感受性の増加につながることを示した.
結論:
- がんにおける広範なメカニズムは,AMPKα1.1.のMAGE-A3/6-TRIM28媒介のユビキチン化と分解によるAMPKα1.1の抑制を伴う.
- このハイジャックされた生殖系メカニズムは,オートファジーのような腫瘍抑制経路を阻害することによって,がん細胞の生存に寄与する.
- このMAGE-A3/6-TRIM28-AMPK軸をターゲットにすることが,MAGE-A3/6再発現を示すがんに対する有望な治療戦略である可能性があります.
関連する概念動画
Regulated Protein Degradation
9.4K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.4K
PI3K/mTOR/AKT Signaling Pathway
6.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression
1.8K
1.8K
The Proteasome
2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
The Proteasome
10.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.7K


